Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal) (TA1111)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 November 2025
Suspected sepsis in under 16s: recognition, diagnosis and early management (NG254)Product type:GuidanceProgramme:NICE guidelinePublished: 19 November 2025
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) (TA1105)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2025
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal) (TA1104)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2025
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal) (TA1100)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 October 2025
DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations: NICE review (NR1)Product type:AdviceProgramme:NICE reviewPublished: 5 September 2025
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 August 2026
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 3 September 2026
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 February 2027
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Digital self-help for eating disorders: early value assessmentStatus:In developmentProgramme:Health technology evaluationExpected publication date: TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intentionStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Epilepsies in children, young people and adultsStatus:In developmentProgramme:NICE guidelineExpected publication date: TBC
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mercaptamine hydrochloride for treating corneal cystine crystal deposits in people 6 months to under 2 years with cystinosis [TSID12261]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Lanadelumab for preventing recurrent attacks of hereditary angioedema in people 2 years and over [TSID12298]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Etavopivat for treating sickle cell disease in people 12 years and over [TSID12320]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [TSID12315]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for managing overweight and obesity in people 12 to 17 years [TSID12322]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC